Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2954 Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors

Introduction: Different treatment modalities have been considered for patients with malignant advanced neuroendocrine tumors(NETs) of the pancreas and duodenum.Aggressive surgery remains a controversial yet an efficacious antitumor therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Athar A,

Keywords: Surgical resection, Advanced NET,

#2944 Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer

Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Salvatici M, Zorzino L, Fabiani I, Cardinale D, Fazio N,

Keywords: sST2, Biomarkers, Carcinoid Heart Disease,

#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,

Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,

#2208 High Hepatic Tumor Burden and History of Cardiovascular Comorbidities Are Associated with Carcinoid Heart Disease: A Multicenter and Multinational Study

Introduction: While 5HT is considered the main causative agent for carcinoid heart disease (CHD, not all pts with elevated 24h-urinary 5HIAA (u5HIAA) develop CHD.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Mesquita M, Alves C, Silva C, Soeiro M,

Keywords: carcinoid heart disease, neuroendocrine, prognostic, carcinoid syndrome,

#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study

Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,

Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.